

⑩



Europäisches Patentamt
European Patent Office
Office européen des brevets

⑪ Publication number:

**0 056 565
B1**

⑫

EUROPEAN PATENT SPECIFICATION

⑬ Date of publication of patent specification: **05.12.84**

⑭ Int. Cl.³: **C 07 C 103/52 // A61K37/02**

⑮ Application number: **81830207.7**

⑯ Date of filing: **26.10.81**

⑰ Derivatives of di(-2-chloroethyl) aminophenyl alanine with antitumour activity.

⑱ Priority: **28.11.80 IT 2630580**

⑲ Date of publication of application:
28.07.82 Bulletin 82/30

⑳ Publication of the grant of the patent:
05.12.84 Bulletin 84/49

㉑ Designated Contracting States:
AT BE CH DE FR GB LI LU NL SE

㉒ References cited:
AU-B- 452 986

㉓ Proprietor: **PROTER S.p.A.**
38 Via Lambro
I-20090 Opera (Milan) (IT)

㉔ Inventor: **De Barbieri, Augusto**
Via Morosini 36
Milan (IT)

㉕ Representative: **Perani, Aurelio et al**
c/o JACOBACCI-CASETTA & PERANI S.p.A 7,
Via Visconti di Modrone
I-20122 Milano (IT)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European patent convention).

Courier Press, Leamington Spa, England.

EP 0 056 565 B1

Description

The present invention relates to derivatives of dichlorodiethylaminophenylalanine which are useful in the treatments of malignant tumours.

Antitumour compounds based on oligopeptides containing m-[di-(2-chloroethyl)amino]-L-phenylalanine are described in AU—B—452,986.

In said compounds the m-[di-(2-chloroethylamino)]-L-phenylalanine is linked through peptide bonds to one or more L-amino-acids to provide respectively di-, or tripeptides.

It is known that in order to value the antitumour activity of an antitumour compound the following models are generally carried out:

- model 1—Inhibition of the growth of Sarcoma 180 in mice;
- model 2—Survival time of BDF₁ mice inoculated intraperitoneally with cells of leukaemia L 1210;
- model 3—Survival time of AKR mice diagnosed for lymphatic leukaemia induced by the GROSS leukaemia virus;
- model 4—Cytocide activity against tumour cells in vitro culture.

With regard to above models, the oligopeptides described in AU—B—452,986 have shown the following behaviours:


- model 1—good inhibition activity of the growth of Sarcoma 180;
- model 2—poor increase of the survival time of BDF₁ mice;
- model 3—no ability of increasing the survival time in AKR mice;
- model 4—from poor to good cytocide activity.

In order to increase the antineoplastic activity of antitumour compound based on oligopeptides containing di-(2-chloroethyl)amino-phenylalanine while maintaining a low to moderate toxicity, the present invention provide a new family of antitumour compounds each of which is characterized in that it comprises a tripeptide formed from the aminoacids dichlorodiethylaminophenylalanine, para-fluorophenylalanine and methionine bonded together by CO—NH peptide links.


The very high antitumour activity of the tripeptides of this invention—compared with that of oligopeptides of AU—B—452,986—is an unexpected result, bearing in mind that the methionine does not own any activity on tumour cells. In this connection it is believed that such unexpected result is due to the fact that methionine is the most important aminoacid in the protein biosynthesis.

In the following description, for the purpose of simplification:


— MPhe indicates the aminoacid dichlorodiethyl-aminophenylalanine having the structural formula



in which the —N(CH₂CH₂Cl)₂ group may be in the ortho, meta or para position,
— pFPhe indicates the aminoacid para-fluorophenylalanine having the structural formula:



— Met indicates the aminoacid methionine of formula:



O 056 565

The result achieved by subsequent systematic research have consistently demonstrated that all the tripeptides formed from the aminoacids specified above have chemotherapeutical activity against tumours and are of limited toxicity, whereby they can all be used to advantage in the treatment of malignant tumours.

5 Thus the invention relates to all the possible permutations of three of the said aminoacids in accordance with the following sequences:

- 1) pFPhe. MPhe. Met
- 10 2) pFPhe. Met. MPhe
- 3) MPhe. pFPhe. Met
- 4) MPhe. Met. pFPhe
- 15 5) Met. pFPhe. MPhe.
- 6) Met. MPhe. pFPhe

20 To advantage, and in accordance with a further characteristic of this invention, the three aminoacids of each anti-tumour compound have a laevo-rotatory (L) configuration in all the sequences specified above.

In the aminoacid dichlorodiethylaminophenylalanine, the $N(CH_2CH_2Cl)_2$ — group may, as stated above, be either in the ortho, meta or para position but this group is preferably in the meta position.

25 Furthermore in several of the sequences listed above, and, more precisely, in sequences 1, 2, 5 and 6, in which the terminal aminoacids are the pFPhe and Met having free NH_2 groups, these aminoacids may be formylated.

The preferred process for the preparation of the tripeptides of the invention comprises essentially the steps of:

- 30 — condensing one of the said aminoacids having a blocked amine group with another of the said aminoacids having a blocked carboxyl group with the aid of dicyclohexylcarbodiimide;
- removing one of the blocking groups to form a dipeptide having a blocked amine or carboxyl group; and
- 35 — condensing the dipeptide with the third aminoacid to form the tripeptide, with the aid of dicyclohexylcarbodiimide. The amine or carboxyl group of the third aminoacid may also be blocked and blocking groups which are not required in the tripeptide to form the compound of the invention are removed in additional steps. Other steps may also be introduced, for example, to form the ester or ester hydrochloride of the tripeptide.

40 In order selectively to protect the functional amine groups, the amine group is acylated, for example, with formic acid or with carbobenzoxy chloride or with other acylating groups which are known in the art. The carboxyl groups are protected, for example, by esterification in the form of methyl, ethyl, propyl or benzyl esters which are subsequently eliminated by cautious saponification or
45 hydrogenolysis. The invention will be more fully described in the following detailed examples of the preparation of one of the tripeptides of the sequence specified above.

Preparation 1:

50 p-fluoro-L-phenylalanyl-m-di(2-chloroethyl)amino-L-phenylalanyl-L-methionine ethyl ester hydrochloride.

a₁) N-formyl-p-fluoro-L-phenylalanyl-m-di(2-chloroethyl)amino-L-phenylalanine ethyl ester.

51.76 g of m-di(2-chloroethyl)amino-L-phenylalanine ethyl ester were dissolved in 300 ml of tetrahydrofuran and 30.74 g of N-formyl-p-fluoro-L-phenylalanine and 31.7 g of dicyclohexylcarbodiimide were successively added to the solution.

55 After three hours of agitation, the course of the reaction was checked chromatographically (TLC) (eluent: n-butanol/acetic acid/water=65:15:25 (v/v/v)).

The dicyclohexylurea was removed by filtration and the filtrate was evaporated at reduced pressure at 40° to small volume. The residue was taken up in ethyl ether to give:

60 50 g of crystalline (68%) product (a₁) with a melting point of 126° to 127°C.

Analysis: N= 8.00% (calculated 7.98%)
Cl=13.32% (calculated 13.47%)

65

0 056 565

b₁) N-formyl-p-fluoro-L-phenylalanyl-m-di(2-chloroethyl)-amino-L-phenylalanine.

52.6 g of a₁) were dissolved in 260 ml of dimethylformamide (DMF) at about 40°C. The solution was then cooled to ambient temperature and 100 ml of 1N aqueous sodium hydroxide solution were added over about 30 minutes.

After one hour under agitation the solution was neutralised by the slow addition of 100 ml of 1N aqueous sodium hydroxide solution were added over about 30 minutes;

After one hour under agitation the solution was neutralised by the slow addition of 100 ml of 1N hydrochloric acid. A white product (b₁) separated, was filtered and washed with cold water (+5°C) and finally with ethyl ether.

Yield: 47.3 g (95%) with a melting point of 157° to 159°C.

Analysis: N= 8.47% (calculated 8.43%)
Cl=14.18% (calculated 14.23%)

c₁) L-methionine ethyl ester.

300 g of L-methionine ethyl ester hydrochloride were supported in a 1N solution of ammonia in chloroform and kept under agitation for 30 minutes under cold conditions (+5°C).

The precipitate which formed was filtered and washed with 400 ml of chloroform. The filtrates were united and evaporated at reduced pressure at 40°C and the residue was taken up with 700 ml of DMF.

The solution contained 1403 moles of methionine ethyl ester, titrated potentiometrically with 0.1N HClO₄.

d₁) N-formyl-p-fluoro-L-phenylalanyl-m-di(2-chloroethyl)-amino-L-phenylalanyl-L-methionine ethyl ester.

55.4 of b₁) were dissolved in 450 ml of DMF with slight heating and were subsequently cooled to 15°C.

A solution of: 17.2 g of N-hydroxysuccinimide (HSI) and 25.5 g of dicyclohexylcarbodiimide (DCC) in 50 ml of DMF were prepared separately.

To the solution of b₁) under vigorous agitation were added of the order of: 70 ml of the solution c₁), equivalent to 0.1235 moles of methionine ethyl ester, then the solution of HSI+DCC. The resulting solution was maintained at 10°/15°C for 30 minutes, then the temperature was allowed to rise to the ambient temperature and agitation was maintained for 16 hours.

Dicyclohexylurea was removed by filtration and washed on the filter with 2×20 ml of DMF.

1800 ml of iced water were added gradually to the united filtrates under agitation so as to maintain the temperature below 20°C.

The product which separated was collected on a filter, washed with water and dried at 40° to 50°C first in a current of air and then under vacuum over P₂O₅.

Yield: 71 g (97.3%) with a melting point of 180°—182°C.

The product obtained was purified by suspension in hot ethyl alcohol and the addition on boiling of a small quantity of DMF until a clear solution was formed.

On cooling a crystalline product was obtained with a melting point of 187°—189°C.

The product d₁) with melting point of 188°—190°C was obtained by crystallisation from tetrahydrofuran.

Analysis: N 8.51% (calculated 8.52%)
Cl 10.71% (calculated 10.78%)
S 4.84% (calculated 4.86%)

e₁) p-fluoro-L-phenylalanyl-m-di-(2-chloroethyl)amino-L-phenylalanyl-L-methionine ethyl ester hydrochloride.

35.5 g of (d₁) were suspended in 500 ml of 1.5 N HCl in ethanol; the mixture was kept under agitation and heated slowly to 60°C. The solution was maintained for 16 hours at ambient temperature and, after a chromatographic (TLC) check, the solution was concentrated at reduced pressure until an oil was formed.

The residue was taken up in ethyl acetate (150 ml) and a saturated aqueous solution of sodium carbonate was added under agitation until the mass had completely dissolved.

The organic phase separated and the aqueous phase was extracted with ethyl acetate (10 ml); the organic extracts were united and washed with 150 ml of cold water and dried with sodium sulphate. The quantity of tripeptide (e₁) present in solution was calculated by potentiometric titration with 0.1 N

HClO₄ in acetic acid.

0056 565

The solution was evaporated at reduced pressure and the residue was taken up with 250 ml of ethanol. To the solution was added 70 ml of ethanol containing the calculated quantity of HCl.

Crystallisation started within a short time.

After resting for 3 to 4 hours, the crystalline product (e_1) was filtered and washed with ethanol, then with ethyl ether and finally dried under vacuum at 80°C over P_2O_5 .

Yield: 23.7 g (66%) with a melting point of 180°—182°C.

	Analysis: N 8.38%	(calculated 8.41%)
	Cl ⁻ 5.30%	(calculated 5.32%)
10	Cl _t 15.85%	(calculated 15.97%)
	S 4.76%	(calculated 4.81%)

Example 2

15 a_2) N-formyl-m-di(2-chloroethyl)-amino-L-phenylalanyl-L-methionine ethyl ester.

66.6 g of N-formyl-m-di(2-chloroethyl)-amino-L-phenylalanine were dissolved in 400 ml of dimethyl formamide (DMF).

To the solution, cooled to 15°C, were added 133 ml of a solution of 0.236 moles of L-methionine ethyl ester in DMF.

20 Subsequently, still at 15°C, a solution of 31.05 g of N-hydroxysuccinimide and 48.6 g of dicyclohexylcarbodiimide in 100 ml of DMF was added.

After 18 hours of agitation at room temperature, the dicyclohexylurea was removed by filtration and washed on the filter with 2x30 ml of DMF. 2 litres of an ice-water mixture were added to the filtrate under agitation at a rate such as to maintain the temperature below 20°C.

25 A white precipitate was collected on the filter, washed with water and dried under vacuum at 40°C.

Yield: 90.5 g (92%) with a melting point of 93°—95°C

30	Analysis: N= 8.49%	(calculated 8.53%)
	Cl=14.44%	(calculated 14.41%)
	S= 6.51%	(calculated 6.52%)

b_2) m-di(2-chloroethyl)amino-L-phenylalanyl-L-methionine ethyl ester hydrochloride.

35 49.2 g of (a_2) were added to 600 ml of a 1.5 N solution of HCl in anhydrous ethyl alcohol. The solution was kept in an Erlenmeyer flask with a ground-glass stopper for 6 hours.

After a chromatographic check (TLC) had revealed the absence of the initial product, the solution was evaporated under reduced pressure at 40°C until an oily residue was left.

40 The residue was taken up with 150 ml of cold water (at +5°C) and a whitish product separated which was dispersed under agitation for 15 minutes; the pH was brought to 3.5 by the addition of an aqueous 10% sodium bicarbonate solution.

The product was collected by filtration, and washed on the filter with cold water. It was dried under vacuum at 40°C over P_2O_5 .

45 Yield: 41.8 g (88.5%) with a melting point of 135°—138°C.

	Analysis: N= 8.79%	(calculated 8.88%)
	Cl ⁻ = 7.51%	(calculated 7.50%)
	S= 6.77%	(calculated 6.78%)
50	Cl _t =22.39%	(calculated 22.79%)

c_2) m-di-(2-chloroethyl)amino-L-phenylalanyl-L-methionine ethyl ester.

55 41.8 g of (b_2) were suspended in 120 ml of chloroform and 100 ml of an aqueous 10% sodium bicarbonate solution were added. The mixture was left under agitation for 15 minutes under cold conditions (+5°C).

The chloroform phase was separated, washed with water, dried, filtered and evaporated under reduced pressure at 40°C.

The oily residue was taken up with 150 ml of tetrahydrofuran.

60 The solution was titrated potentiometrically with 0.1 N $HClO_4$ in acetic acid. There were 0.083 moles of c_2) in the solution.

d_2) p-fluoro-L-phenylalanyl-m-di-(2-chloroethyl)-amino-L-phenylalanyl-L-methionine ethyl ester hydrochloride.

65 To a solution of 17.5 g of N-formyl-p-fluoro-L-phenylalanine in 180 ml of tetrahydrofuran were added solution (c_2) and then 18.5 g of dicyclohexylcarbodiimide.

Agitation was maintained for 6 hours and the course of the reaction was checked by TLC. The dicyclohexylurea was removed by filtration and the filtrate was poured into 1800 ml of cold water (+5°C). The suspension was brought to a pH of 3.5 with 2 N HCl and, after 15 minutes of agitation under cold conditions, the voluminous white product was collected by filtration and washed 5 on the filter with cold water. The product was dried under vacuum at 40°C over P₂O₅.

10 Analysis: N= 8.40% (calculated 8.41%)
Cl⁻= 5.33% (calculated 5.32%)
Cl_t=15.89% (calculated 15.97%)
S= 4.82% (calculated 4.81%)

— Inhibition of the growth of sarcoma 180 by the process established by CCNSC (Cancer Chemotherapy National Service Center U.S. Dept. of Health Education and Welfare, Cancer Chemotherapy Reports No. 25 Dec. 1962).

Aqueous solutions stabilised with carboxymethylcellulose were administered intraperitoneally or subcutaneously on the first, third, fifth and seventh days after the tumour inoculum; on the ninth day the animals were killed and the weight of the tumours; their percentage variation compared to controls, the weight of the spleen and the body weight were measured.

30 — Determination of the mean survival time (mean survival time=MST) of BDF₁ mice, inoculated intraperitoneally with 10⁶ cells of lymphatic leukaemia L1210 taken from regular implants in DBA2 mice. The MST both of controls and of the treated mice was determined and then the increased lifespan (ILS) was determined as set out in "Cancer Chemotherapy Reports" 1972 vol. 3 n 2 (Protocols for Screening Chemical Agents and Natural Products). Against animal Tumours and other biological System—third Edition national Cancer Inst. Bethesda Maryland.

35 The compounds were tested by injection intraperitoneally or subcutaneously 24 or 48 hours after the tumour inoculum either in a single massive dose or with fractions of the dose at intervals of 8 days, progressively reduced.

The tripeptide pPhe, mPhe, MetOEtHCl was also tested in AKR mice diagnosed for lymphatic leukaemia induced by the Gross leukaemia virus. At the very beginning of the test the condition of the leukaemic mice was as follows.

average weight of the spleen—	565 mg per mouse
leukaemic cells—	20,000 per cubic micro-litre.

45 A single dose of 18–20 mg/kg was injected intraperitoneally or subcutaneously into each mouse.

This dose was not found to be toxic for the non-leukaemic mice while the treatment mice experienced a complete clinical recovery within two days of injection, with normal blood structure, normalization of the thymus and normal spleen with no indication of cellular colonization.

0056 565

Activity of some compounds of the present invention on the throw back of sarcoma 180 on mouse

	Compounds	Doses in mg/kg	Throw back % on tumours	Casualties in the treated group
5	1. pFPhe. m-MPhe. MetOEt. HCl	8	85,38	0/6
	"	16	96,66	3/6
	2. "	8	70,88	0/6
	"	16	89,51	0/6
10	3. "	8	86,47	0/6
	"	16	97,53	3/6
	4. "	8	62,73	0/6
15	"	16	90,14	1/6
	5. "	8	70,23	0/6
	"	16	91,21	2/6
20	6. "	8	85,00	0/6
	"	16	93,94	1/6
	7. "	8	79,70	0/6
	"	16	93,64	1/6
25	1. CHO. Met. m-MPhe. pFPheOEt. HCl	8	76,32	0/6
	"	16	88,04	0/6
	2. "	8	71,33	0/6
30	"	16	73,93	0/6
	3. "	8	74,17	0/6
	"	16	87,00	0/6
35	4. "	10	80,42	0/6
	"	16	93,89	3/6
	"	22	96,77	3/6

40 Claims

1. Anti-tumour compound characterised in that it comprises a tripeptide formed from the aminoacids dichlorodiethylaminophenylalanine, para-fluorophenylalanine and methionine bonded together by CO—NH-peptide links.
2. Anti-tumour compound according to Claim 1, characterised in that each said aminoacid has a laevo-rotatory configuration.
3. Anti-tumour compound according to Claim 1 or Claim 2, characterised in that the tripeptide comprises a dichlorodiethylaminophenylalanine bonded by peptide links to para-fluorophenylalanine and methionine respectively.
4. Anti-tumour compound according to any one of Claims 1, 2 and 3, characterised in that it is constituted by an ester or ester hydrochloride of the said tripeptide.
5. Anti-tumour compound according to any one of Claims 1 to 4, characterised in that the terminal amine group of the tripeptide belongs to the parafluorophenylalanine or methionine and is formylated.
6. Anti-tumour compound constituted by p-fluoro-L-phenylalanyl-m-di(2-chloroethyl)-amino-L-phenylalanyl-L-methionine ethyl ester hydrochloride.
7. Process for the preparation of an anti-tumour compound according to any one of the preceding claims, characterised in that it includes the steps of:
 - condensing one of the said aminoacids having a blocked amine group with another of the said aminoacids having a blocked carboxyl group with the aid of dicyclohexylcarbodiimide;
 - removing one of the blocking groups to form a dipeptide having a blocked amine or carboxyl group; and
 - condensing the dipeptide with the third aminoacid to form the tripeptide, with the aid of dicyclohexylcarbodiimide.

8. Process for the preparation of an anti-tumour compound according to Claim 7, characterised in that it includes the steps of:

- condensing one of the said aminoacids having a blocked amine group with another of the said aminoacids having a blocked carboxyl group with the aid of dicyclohexylcarbodiimide;
- removing one of the blocking groups to form a dipeptide having a blocked amine or carboxyl group;
- condensing the dipeptide with the third amino acid to form a tripeptide, with the aid of dicyclohexylcarbodiimide; and
- removing the other blocking group to form the required tripeptide.

10

9. Process according to Claim 7 or Claim 8, characterised in that the amine or carboxyl group of the third aminoacid reacted with the dipeptide is blocked and the process includes a further step of removing the blocking group of the said third aminoacid.

15 Patentansprüche

1. Anti-Tumor-Verbindung, dadurch gekennzeichnet, daß sie aus einem Tripeptid besteht, das aus den Aminosäuren Dichlordiäthylaminophenylalanin, para-Fluorphenylalanin und Methionin besteht, die durch CO—NH-Peptid-Bindungen miteinander verbunden sind.

20 2. Anti-Tumour-Verbindung nach Anspruch 1, dadurch gekennzeichnet, daß jede dieser Aminosäuren in linksdrehender Konfiguration vorliegt.

3. Anti-Tumour-Verbindung nach Anspruch 1 oder Anspruch 2, dadurch gekennzeichnet, daß das Tripeptid aus Dichlordiäthylaminophenylalanin besteht, das durch Peptidbindungen an para-Fluorphenylalanin beziehungsweise Methionin gebunden ist.

25 4. Anti-Tumour-Verbindung nach einem der Ansprüche 1, 2 oder 3, dadurch gekennzeichnet, daß es aus einem Ester oder Esterhydrochlorid dieses Tripeptids besteht.

5. Anti-Tumour-Verbindung nach einem der Ansprüche 1 bis 4, dadurch gekennzeichnet, daß die endständige Aminogruppe des Tripeptids dem para-Fluorphenylalanin oder dem Methionin angehört und formyliert ist.

30 6. Anti-Tumour-Verbindung, bestehend aus p-Fluor-L-phenylalanyl-L-methionin-äthylester-hydrochlorid.

7. Verfahren zur Herstellung einer Anti-Tumour-Verbindung gemäß einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, daß es folgende Schritte einschließt:

35 — Kondensierung einer der erwähnten Aminosäuren, deren Aminogruppe blockiert ist, mit einer anderen der erwähnten Aminosäuren, deren Carboxylgruppe blockiert ist, mit Hilfe von Dicyclohexylcarbodiimid;

— Entfernung einer der blockierenden Gruppen, wodurch man ein Dipeptid erhält mit einer blockierten Aminoo oder Carboxylgruppe; und

40 — Kondensierung des Dipeptids mit der dritten Aminosäure mit Hilfe von Dicyclohexylcarbodiimid, um das Tripeptid zu bilden.

8. Verfahren zur Herstellung einer Anti-Tumour-Verbindung nach Anspruch 7, dadurch gekennzeichnet, daß es folgende Schritte einschließt:

45

— Kondensierung einer der erwähnten Aminosäuren, deren Aminogruppe blockiert ist, mit einer anderen der erwähnten Aminosäuren, deren Carboxylgruppe blockiert ist, mit Hilfe von Dicyclohexylcarbodiimid;

50 — Entfernung einer der blockierenden Gruppen, wodurch man ein Dipeptid erhält mit einer blockierten Amino- oder Carboxylgruppe;

— Kondensierung des Dipeptids mit der dritten Aminosäure mit Hilfe von Dicyclohexylcarbodiimid, um ein Tripeptid zu bilden; und

— Entfernung der anderen blockierenden Gruppe zur Bildung des gewünschten Tripeptids.

55

9. Verfahren nach Anspruch 7 oder 8, dadurch gekennzeichnet, daß die Amino- oder Carboxylgruppe der dritten Aminosäure, die mit dem Dipeptid zur Reaktion gebracht wird, blockiert ist, und daß das Verfahren einen weiteren Schritt der Entfernung der blockierenden Gruppe dieser dritten Aminosäure einschließt.

60

Revendications

1. Composé antitumoral, caractérisé en ce qu'il comprend un tripeptide formé à partir des aminoacides dichlorodiéthylaminophénylalanine, para-fluorophénylalanine et méthionine unis par des liaisons peptidiques CO—NH.

65

2. Composé antitumoral suivant la revendication 1, caractérisé en ce que chacun des amino-acides a la configuration lévogyre.

3. Composé antitumoral suivant la revendication 1 ou 2, caractérisé en ce que le tripeptide comprend de la dichlorodiéthylaminophénylalanine unie par des liaisons peptidiques à la parafluorophénylalanine et à la méthionine, respectivement.

4. Composé antitumoral suivant l'une quelconque des revendications 1, 2 et 3, caractérisé en ce qu'il consiste en un ester ou chlorhydrate d'ester du tripeptide.

5. Composé antitumoral suivant l'une quelconque des revendications 1 à 4, caractérisé en ce que le radical amino terminal du tripeptide appartient à la parafluorophénylalanine ou à la méthionine et est formylé.

6. Composé antitumoral constitué par le chlorhydrate d'ester éthylique de p-fluoro-L-phényl-alanyl-m-di(2-chloroéthyl)amino-L-phénylalanine-L-méthionine.

7. Procédé de préparation d'un composé anti-tumoral suivant l'une quelconque des revendications précédentes, caractérisé en ce qu'il comprend les stades:

- de condenser un des aminoacides ci-dessus comprenant un radical amino bloqué avec un autre de ces aminoacides comprenant un radical carboxyle bloqué, à l'aide de dicyclohexylcarbodiimide;
- d'éliminer un des radicaux de blocage pour former un dipeptide comprenant un radical amino ou carboxyle bloqué, et
- de condenser le dipeptide avec le troisième aminoacide pour former le tripeptide, à l'aide de dicyclohexylcarbodiimide.

8. Procédé de préparation d'un composé antitumoral suivant la revendication 7, caractérisé en ce qu'il comprend les stades:

- de condenser un des aminoacides ci-dessus comprenant un radical amino bloqué avec un autre de ces aminoacides comprenant un radical carboxyle bloqué, à l'aide de dicyclohexylcarbodiimide;
- d'éliminer un des radicaux de blocage pour former un dipeptide comprenant un radical amino ou carboxyle bloqué;
- de condenser le dipeptide avec le troisième aminoacide pour former le tripeptide, à l'aide de dicyclohexylcarbodiimide, et
- d'éliminer l'autre radical de blocage pour former le tripeptide requis.

9. Procédé suivant la revendication 7 ou 8, caractérisé en ce que le radical amino ou carboxyle du troisième aminoacide ayant réagi avec le dipeptide est bloqué et le procédé comprend le stade supplémentaire d'éliminer le radical de blocage de ce troisième aminoacide.